Emergent signs $480M manufacturing deal with Johnson & Johnson for Covid-19 vaccine

Emergent BioSolutions Inc. said Monday it has signed a five-year agreement with Johnson & Johnson to manufacture its Covid-19 vaccine candidate, just a couple of months after striking a $135 million deal for the first step of their collaboration. For the first two years of the deal, valued at $480 million, the Gaithersburg biotech will serve as a contract development and manufacturing organization (CDMO) to Janssen Pharmaceuticals, Inc., part of New Brunswick, New Jersey-based Johnson & Johnson…